hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06371053, orgStudyIdInfo id: community - dementia, briefTitle: The Effect of Community Intervention on Different Degrees of Dementia, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2024-05, completionDateStruct date: 2024-05, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Babujinaya Cela, class: OTHER_GOV, descriptionModule briefSummary: The goal of this clinical trial is to explore the impact of Community Intervention on Dementia and Activities of Daily Living in community-dwelling elderly individuals (≥60 year old) with Alzheimer's disease. It primarily aims to address: the effects of Community Intervention on Dementia and Activities of Daily Living in community-dwelling elderly individuals with Alzheimer's disease in different degrees. All participants are required to undergo a continuous 2-week (14 days) Community Intervention, with weekends off and training conducted only on weekdays. The training will be conducted two sessions per day, lasting 30 minutes each., conditionsModule conditions: Alzheimer Disease, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 200, type: ESTIMATED, armsInterventionsModule interventions name: Community Intervention, outcomesModule primaryOutcomes measure: Mini-Mental State Examination, secondaryOutcomes measure: Barthel Index, secondaryOutcomes measure: Functional near-infrared spectroscopy, eligibilityModule sex: ALL, minimumAge: 60 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06371040, orgStudyIdInfo id: V1.0, CART-20230619, briefTitle: Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-03-01, completionDateStruct date: 2026-12-01, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Ting Chang, MD, class: OTHER, descriptionModule briefSummary: This study is a single-center, open-label, single-arm, dose-exploration study to evaluate the safety and preliminary effectiveness of CD19-BCMA CAR-T in the treatment of refractory, generalized myasthenia gravis. The study is a dose escalation trial in adult, refractory, systemic MG patients. The Keyboard method will be used to perform dose escalation to explore the maximum tolerated dose (MTD). A total of 12 MG patients who meet the inclusion criteria are expected to be recruited., conditionsModule conditions: Myasthenia Gravis, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SEQUENTIAL, interventionModelDescription: CD19-BCMA Targeted CAR-T Dose 1 5.0 e5/ kg CD19-BCMA CAR-T positive T cellsCD19-BCMA Targeted CAR-T Dose 2 1.5 e6/ kg CD19-BCMA CAR-T positive T cellsCD19-BCMA Targeted CAR-T Dose 2 5 e6/ kg CD19-BCMA CAR-T positive T cells, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 12, type: ESTIMATED, armsInterventionsModule interventions name: CD19-BCMA Targeted CAR-T Dose 1, interventions name: CD19-BCMA Targeted CAR-T Dose 2, interventions name: CD19-BCMA Targeted CAR-T Dose 2, outcomesModule primaryOutcomes measure: Frequency, type, and severity of adverse events, secondaryOutcomes measure: Frequency, type, and severity of abnormal laboratory indicators related to treatment, secondaryOutcomes measure: Changes of blood pressure, secondaryOutcomes measure: Changes of pulse rate, secondaryOutcomes measure: Changes of weight, secondaryOutcomes measure: Changes of Myasthenia Gravis Activities of Daily Living (MG-ADL) scores, secondaryOutcomes measure: Changes of Quantitative Myasthenia Gravis (QMG) scores, secondaryOutcomes measure: Changes of Myasthenia Gravis Composite (MGC) scores, secondaryOutcomes measure: Proportion of subjects who achieved improvement, secondaryOutcomes measure: Time to achieve clinical improvement, secondaryOutcomes measure: Changes of myasthenia gravis-specific autoantibody titers, secondaryOutcomes measure: Changes of immunoglobulins, otherOutcomes measure: Changes in proportion of peripheral blood immune cell, otherOutcomes measure: serum inflammatory markers levels, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Tangdu Hospital, The Fourth Military Medical University, city: Xi'an, state: Shaanxi, zip: 710038, country: China, geoPoint lat: 34.25833, lon: 108.92861, hasResults: False
protocolSection identificationModule nctId: NCT06371027, orgStudyIdInfo id: RECO6U/22-2022, briefTitle: Novel Silk Fibroin Nanofiber Membrane Using Minimally Invasive Surgery in Treatment of Periodontal Intrabony Defects: A Randomized Clinical Trial, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-11-01, primaryCompletionDateStruct date: 2024-02-15, completionDateStruct date: 2024-04-01, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: October 6 University, class: OTHER, descriptionModule briefSummary: Clinically and radiographically by cone beam CT evaluate the regenerative potentials of silk fibroin (SF) nanofiber membrane, using minimally invasive surgery, for the regenerative treatment of intrabony periodontal defects., conditionsModule conditions: Intrabony Periodontal Defect, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 30, type: ACTUAL, armsInterventionsModule interventions name: Minimally Invasive Surgery Technique (MIST) + Novel Silk Fibroin (SF) nanofiber membrane, interventions name: Minimally Invasive Surgery Technique (MIST) + collagen membrane, interventions name: Minimally Invasive Surgery Technique (MIST), outcomesModule primaryOutcomes measure: Novel Silk Fibroin Nanofiber Membrane using minimally invasive surgery in Treatment of Periodontal Intrabony Defects, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: faculty of dentistry O6U, city: Giza, country: Egypt, geoPoint lat: 30.00808, lon: 31.21093, hasResults: False
protocolSection identificationModule nctId: NCT06371014, orgStudyIdInfo id: Ondansetron mouth soluble film, briefTitle: Comparative Study on the Efficacy and Safety of Ondansetron Oral Membrane for the Prevention of Vomiting During Moderate Hypoemetic Chemotherapy, acronym: Ondansetron, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2024-12-30, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Shanghai Children's Medical Center, class: OTHER, descriptionModule briefSummary: Children aged 4-15 years scheduled to receive Moderate or low emetic chemotherapy were randomly assigned to arm-A (Ondansetron mouth soluble film) or arm-B (Ondansetron tablet). Children recruited to arm-A received ondansetron mouth soluble film plus dexamethasone. Children recruited to arm-B received Ondansetron tablet plus dexamethasone. Ondansetron and dexamethasone were given continuously until 48hours after completion of chemotherapy. The primary end point of the study was to determine the proportion of patients who achieved a CR, defined as no vomiting, no retching, and no use of rescue medication, the proportion of patients who achieved a CR during the acute phase (0-24 hours) after administration of the last dose of chemotherapy. Secondary end points were the proportion of patients who achieved a CR during the 24-120 hours (delayed phase) and overall after administration of the last dose of chemotherapy, conditionsModule conditions: To Analyze and Compare the Efficacy and Safety of Ondansetron and Tablet for the Prevention of Moderate and Hypoemetic Chemotherapy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 200, type: ESTIMATED, armsInterventionsModule interventions name: Ondansetron oral membrane, outcomesModule primaryOutcomes measure: Complete Remission Rates in the Acute Phases, secondaryOutcomes measure: Complete Remission Rates in the Delayed Phases, eligibilityModule sex: ALL, minimumAge: 4 Years, maximumAge: 15 Years, stdAges: CHILD, hasResults: False
protocolSection identificationModule nctId: NCT06371001, orgStudyIdInfo id: Helicobacter Pyloi and CKD, briefTitle: Prevalance Of Helicobacter Pylori Infection In Chonic Kidney Diseased Patient Admitted To Luxor Medical Complex, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-05-01, completionDateStruct date: 2025-07-01, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Assiut University, class: OTHER, descriptionModule briefSummary: Detect prevalence of Helicobacter pylori infection in chronic kidney diseased patient admitted to Luxor medical complex and possible role of Helicobacter pylori in pathogenesis of chronic kidney diseased patient of unknown etiology, conditionsModule conditions: Chronic Kidney Diseases, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 122, type: ESTIMATED, armsInterventionsModule interventions name: disease, outcomesModule primaryOutcomes measure: Helicobacter pylori infection and Chronic kidney diseased patient, secondaryOutcomes measure: possible role of H pylori in pathogenesis of chronic kidney diseased patient of unkown etiology, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06370975, orgStudyIdInfo id: Fluid resuscitation in trauma, briefTitle: Effect of Fluid Resuscitation on Lactate in Traumatic Injury Patients, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-08-01, primaryCompletionDateStruct date: 2025-08, completionDateStruct date: 2025-09, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Assiut University, class: OTHER, descriptionModule briefSummary: The study aims to investigate the effect of 3% hypertonic saline resuscitation on lactate clearance in comparison to ringer's lactated solution and 0.9% normal saline in traumatic injury patients.Also to provide insights into the optimal fluid resuscitation strategy for traumatic injury patients, conditionsModule conditions: Fluid Resuscitation, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 150, type: ESTIMATED, armsInterventionsModule interventions name: 3% hypertonic Saline, interventions name: Ringer's lactated solution, interventions name: 0.9% Normal saline, outcomesModule primaryOutcomes measure: Rate of lactate clearance following resuscitation with different solutions, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06370949, orgStudyIdInfo id: 2024-01/17, briefTitle: The Effectiveness of Bupivacaine and Bupivacaine+Dexmedetomidine Combination in Transversus Abdominis Plane* Block, acronym: TAP, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2024-09-30, completionDateStruct date: 2024-11-30, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, class: OTHER, descriptionModule briefSummary: Transversus abdominis plane (TAP) block is an anesthesia method that provides somatic analgesia to the anterior and lateral abdominal walls. Thus, TAP block is widely implemented in perioperative management of colorectal cancer patients.Researchers aimed to evaluate the analgesic effectiveness and duration of effect of dexmedetomidine added to bupivacaine in the TAP block applied in colorectal cancer surgeries., conditionsModule conditions: Colorectal Cancer, conditions: Colorectal Neoplasms, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 84, type: ESTIMATED, armsInterventionsModule interventions name: Bupivacain, interventions name: bupivacain+dexmedetomidine, outcomesModule primaryOutcomes measure: Analgesic effectiveness of bupivacain and bupivacain+dexmedetomidine combination in colorectal cancer surgery, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Turkey Dr.Abdurrahman Yurtaslan Ankara Oncology Train and Research Hospital, city: Ankara, state: Cankaya, zip: 06110, country: Turkey, contacts name: Hazal E Guran Aytug, MD, role: CONTACT, phone: 05078448449, email: drekinguran@gmail.com, geoPoint lat: 39.91987, lon: 32.85427, hasResults: False
protocolSection identificationModule nctId: NCT06370845, orgStudyIdInfo id: 0000-00000; kt24timper, briefTitle: Abundance of a Natural Odour in Human Cerebrospinal Fluid After Olfactory Exposure, acronym: OLFO-Brain, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2024-08-31, completionDateStruct date: 2024-10-30, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: University Hospital, Basel, Switzerland, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to investigate the abundance of a natural odour in human cerebrospinal fluid in obese and lean participants after inhalation thereof. Participants will undergo blood sample collection and inhalation of either a natural odour or placebo through an inhaler in addition to a liquor puncture prescribed in standard of care context., conditionsModule conditions: Overweight and Obesity, designModule studyType: INTERVENTIONAL, phases: EARLY_PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 32, type: ESTIMATED, armsInterventionsModule interventions name: Inhalation - Natural Odour, interventions name: Inhalation - Placebo, outcomesModule primaryOutcomes measure: Detection of a natural odour in human CSF, secondaryOutcomes measure: Abundance of a natural odour in human CSF of obese versus lean participants, secondaryOutcomes measure: Change in abundance of a natural odour in blood before and after olfactory stimulation in relation to abundance in human CSF., secondaryOutcomes measure: Change in abundance of a natural odour in blood before and after olfactory stimulation in obese as compared to lean participants., eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: University Hospital Basel, city: Basel, zip: 4031, country: Switzerland, contacts name: Katharina Timper, Prof. Dr. med., role: CONTACT, phone: 0041 61 328 57 42, email: katharina.timper@usb.ch, contacts name: Isabel M Hofer, role: CONTACT, phone: 0041 61 328 68 14, email: isabelmarie.hofer@usb.ch, geoPoint lat: 47.55839, lon: 7.57327, hasResults: False
protocolSection identificationModule nctId: NCT06370819, orgStudyIdInfo id: NN9541-4923, secondaryIdInfos id: U1111-1292-3441, type: OTHER, domain: Universal Trial Number, secondaryIdInfos id: 2023-506381-32, type: OTHER, domain: EU CT Number, briefTitle: A Research Study Looking Into Blood Levels of the Medicine NNC0519-0130 in the Body in Participants With Normal or Reduced Kidney Function, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2025-04-19, completionDateStruct date: 2025-04-19, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Novo Nordisk A/S, class: INDUSTRY, descriptionModule briefSummary: NNC0519-0130 is a new medicine to improve the treatment options for people living with type 2 diabetes and people with overweight. In this study one dose of NNC0519-0130 will be given and blood levels of NNC0519-0130 will be compared between people with reduced kidney function and people with normal kidney function. The study will last up to 52 days including a screening phase of up to 28 days prior to dosing., conditionsModule conditions: Diabetes Mellitus, Type 2, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 36, type: ESTIMATED, armsInterventionsModule interventions name: NNC0519-0130, outcomesModule primaryOutcomes measure: Area under the curve (AUC)0-∞,NNC0519-0130,SD: Area under the NNC0519-0130 plasma concentration-time curve after a single dose in participants with normal function, and mild, moderate and severe impairment, secondaryOutcomes measure: Maximum concentration (Cmax),NNC0519-0130,SD: Maximum observed NNC0519-0130 plasma concentration after a single dose in participants with normal function, and mild, moderate and severe impairment, secondaryOutcomes measure: AUC0-∞,NNC0519-0130,SD: Area under the NNC0519-0130 plasma concentration-time curve after a single dose in participants with kidney failure, secondaryOutcomes measure: Cmax,NNC0519-0130,SD: Maximum observed NNC0519-0130 plasma concentration after a single dose in participants with kidney failure, secondaryOutcomes measure: Number of adverse events, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Charité Research Organisation GmbH, city: Berlin, zip: 10117, country: Germany, geoPoint lat: 52.52437, lon: 13.41053, hasResults: False
protocolSection identificationModule nctId: NCT06370780, orgStudyIdInfo id: 5UG3AI176592-02, type: NIH, link: https://reporter.nih.gov/quickSearch/5UG3AI176592-02, briefTitle: Exploring, Predicting, and Intervening on Long-term Viral Suppression Electronically, acronym: EPI-LoVE, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-09, primaryCompletionDateStruct date: 2025-04-30, completionDateStruct date: 2025-04-30, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: University of California, Los Angeles, class: OTHER, collaborators name: Florida State University, collaborators name: University of California, Irvine, collaborators name: University of North Carolina, Chapel Hill, collaborators name: AIDS Healthcare Foundation, descriptionModule briefSummary: Despite the widespread availability of effective antiretroviral therapy (ART) in the United States, there remains significant numbers of people living with HIV (PLWH) who fail to achieve and or maintain viral suppression (VS). Disparities persist with the lowest levels of VS among Black individuals, people who use drugs, youth ages 18-24 and people residing in rural areas. Investigators will examine the syndemics underlying these outcomes including substance use, mental health, and barriers to HIV care including racial discrimination, stigma and rural isolation., conditionsModule conditions: HIV Infections, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: OTHER, maskingInfo masking: NONE, maskingDescription: N/A - all participants get the app, enrollmentInfo count: 1000, type: ESTIMATED, armsInterventionsModule interventions name: EPI LOVE, outcomesModule primaryOutcomes measure: Incidence of HIV Viral Suppression, primaryOutcomes measure: Level of Adherence to HIV medication, primaryOutcomes measure: Level of Adherence based on HIV appointments, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of California, Los Angeles, status: RECRUITING, city: Los Angeles, state: California, zip: 90095, country: United States, contacts name: Pamina Gorbach, DrPh, MHS, role: CONTACT, phone: 310-794-2555, email: pgorbach@ucla.edu, contacts name: Valerie El-Alfi, MA, role: CONTACT, email: velalfi@mednet.ucla.edu, geoPoint lat: 34.05223, lon: -118.24368, hasResults: False
protocolSection identificationModule nctId: NCT06370754, orgStudyIdInfo id: 2401289-19-2403, briefTitle: Newly Emerging Immunotherapy for Pancreatic Cancer Treatment, acronym: FD-IMPACT, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-30, primaryCompletionDateStruct date: 2026-04-30, completionDateStruct date: 2027-04-30, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Fudan University, class: OTHER, descriptionModule briefSummary: This is a Phase Ib/II platform clinical study to evaluate the initial efficacy and safety of different novel immunotherapies in patients with advanced pancreatic cancer., conditionsModule conditions: Pancreatic Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 117, type: ESTIMATED, armsInterventionsModule interventions name: JS001, interventions name: JS004, interventions name: JS007, interventions name: JS015, interventions name: Irinotecan Liposome Injection, interventions name: 5-Fluorouracil (5-FU), interventions name: Leucovorin (LV), interventions name: Nab paclitaxel, interventions name: Gemcitabine, outcomesModule primaryOutcomes measure: Incidence of dose-limiting toxicity (DLT) (phase IB), primaryOutcomes measure: Objective Response Rate (ORR) (phase II), secondaryOutcomes measure: Objective Response Rate (ORR) (phase IB), secondaryOutcomes measure: Disease control rate (DCR), secondaryOutcomes measure: Duration of Response (DOR), secondaryOutcomes measure: Progression free survival (PFS), secondaryOutcomes measure: Overall Survival (OS), secondaryOutcomes measure: Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University, city: Shanghai, state: Shanghai, zip: 200032, country: China, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False